Summary

Introduction of Acute Care Syndromic Testing

The acute care syndromic testing market was valued at $3.14 billion in 2022 and is expected to reach $8.44 billion by 2033, growing at a CAGR of 9.43% between 2023 and 2033. Syndromic panels are molecular diagnostics tests that can detect more than one pathogen at the same time. These pathogens generally have similar or overlapping clinical symptomatology, which enables better management of patients and easier diagnosis with respect to certain symptoms.

Market Introduction

Before the advent of syndromic tests’ physicians relied on the single-plex test, which could detect one pathogen at a time, and multiple tests had to be done to finally identify the pathogen causing the disease. Additionally, till all the tests were completed, physicians had to rely on general therapy until definitive results were available. This delayed the treatment process. As per BIS research, the acute care syndromic testing market includes panels and instruments that can test for more than one type of pathogen and specific instruments that are used to perform these tests. These are predominantly polymerase chain reaction-based testing kits, panels, or assays. The most common syndromic testing panels include respiratory, gastrointestinal, genitourinary, and tropical diseases, among others.

Industrial Impact

The global acute care syndromic testing market has witnessed significant growth, attributed to the increasing demand for early detection of infectious diseases. The increasing prevalence of infectious diseases and the increasing occurrence of pandemics have played a critical role in market growth. Furthermore, the rising temperature of the planet and the detection of new infectious disease in regions around the world is also influencing the market growth.

Global acute care syndromic testing has immense potential to deliver the next level of healthcare solutions. For instance, in April 2023, Abbott Laboratories partnered with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which is a group of more than 100 scientists globally in various academia and public health agencies. With this partnership, they plan to use diagnostic testing and data science technologies to mitigate future disease outbreaks. Additionally, the advent of better diagnosing, predicting, treating, and monitoring tools for infectious diseases is driving the acute care syndromic testing market growth. Other factors also impact the market growth, including increased patient demand and low turnaround time of these tests.

Market Segmentation:

Segmentation 1: by Disease Type
• Respiratory Diseases
o Upper Respiratory Tract Infections
o Lower Respiratory Tract Infections
• Gastrointestinal Diseases
• Genitourinary Diseases
o Urinary Tract Diseases
o Sexually Transmitted Diseases
• Tropical Diseases
• Other Disease Types

Respiratory Diseases Segment to Dominate the Global Acute Care Syndromic Testing Market (by Disease Type)

The acute care syndromic testing market is led by the respiratory panels, with a 56.29% share in 2022. The burden of viral respiratory illnesses and pneumonia is huge, and thus syndromic diagnostic testing is a good and fast approach to distinguish between viral and bacterial respiratory pathogens and should be implemented by hospitals and doctors aiming to optimize antimicrobial use.

Segmentation 2: by Target
• Bacteria
• Viruses
• Fungi
• Parasites

Bacteria Segment to Dominate the Global Acute Care Syndromic Testing Market (by Target)

The acute care syndromic testing market is led by bacteria panels, with a 41.65% share in 2022. Bacteria are microbes that have a simple cell structure with a control center that contains genetic information, and the DNA is contained in a single loop. Bacterial can cause numerous types of infections that can affect humans as well as animals. These infections can affect the skin, brain, lungs, blood, or any other body part of the human body. The infection increases as the bacteria multiply and that increase the area of infection.

Segmentation 3: by Sample Type
• Blood
• Urine
• Biofluids
• Stool
• Swabs
• Others

Swabs Segment to Dominate the Global Acute Care Syndromic Testing Market (by Sample Type)

The acute care syndromic testing market is led by swabs, with a 51.90% share in 2022. The key reason for the increasing popularity of swabs is that it is an easy-to-use, non-invasive, and inexpensive sampling method.

Segmentation 4: by End User
• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Hospitals Segment to Dominate the Global Acute Care Syndromic Testing Market (by End User)

The acute care syndromic testing market is led by hospitals, with a 42.53% share in 2022. Hospitals are also at the forefront of adopting syndromic testing panels into routine healthcare procedures. Hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific, have incorporated syndromic testing panels and assays to provide superior care to patients.

Segmentation 5: by Region

• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific - Japan, India, China, South Korea, Australia, and Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

North America held the highest market share at 40.41% in 2022, mainly due to the high number of legacy companies in the region. Further, increasing approvals and synergistic activities are also increasing their dominance in the market. However, the highest CAGR in the market was seen by Asia-Pacific at 10.97% due to the increasing adoption of syndromic panels in the region, especially in highly populated countries such as China and India.

Recent Developments in the Acute Care Syndromic Testing Market

• In May 2023, Hologic, Inc. got FDA clearance for its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. This molecular diagnostic test can test for the most prevalent respiratory viruses exhibiting similar conditions all at once, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B), and respiratory syncytial virus (RSV).
• In March 2023, Lucira Health got FDA approval for its home testing kit that can detect respiratory infections, including COVID-19 and flu. It is easy to use at-home test and can be done on children as young as two years old.
• In April 2023, Abbott Laboratories partnered with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which is a group of more than 100 scientists globally in various academia and public health agencies. With this partnership, they plan to use diagnostic testing and data science technologies to mitigate future disease outbreaks.
• In May 2023, Applied BioCode, Inc. made an agreement with Medline Industries, which is an industry leader in distributing healthcare products. Medline Industries agreed to distribute the MDx-3000 system, which enables the diagnosis of gastrointestinal and upper respiratory infections, in addition to a suite of Analyte Specific Reagents (ASRs).
• In April 2023, QIAGEN N.V. announced the availability of its QIAstat-Dx syndromic testing solution in Japan, which can detect more than 20 respiratory pathogens, including SARS-CoV-2, from a single sample.
• In January 2023, Fusion Genomics established a fully automated, first-of-its-kind facility for infectious disease surveillance at the Toronto Pearson Internation Airport. This facility is using the company's ONETest platform for the detection of SARS-CoV-2 and other respiratory pathogens in wastewater.

Demand – Drivers, Challenges, and Opportunities

Market Demand Drivers:

Faster Results Acquired with Syndromic Tests: The traditional single-plex testing methods for infectious disease detection use methods such as microscopy and bacterial culture, whereas syndromic multi-plex tests use PCRs. This is where syndromic testing really shines, as PCR testing is more accurate and less time-consuming. These quick and comprehensive results then allow physicians to provide better care for the patients and make faster clinical decisions.

Increasing Incidence of Infectious Diseases: The global health system is undergoing severe change as the incidence of infectious diseases constantly increases and building a system against known and unknown pathogen threats. Governments from all over the world have joined hands to maintain the risk of the pandemic at all levels, including the different regional levels such as local, national, and regional. Even though this global health system is doing a lot to protect and promote human health, the world is always being confronted by numerous emerging, reemerging, and longstanding infectious diseases.

Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing: Diagnosis of infectious diseases can be made much easier with the help of syndromic testing. This benefits not only the individual patient but the institution as a whole in numerous ways, especially by decreasing the costs for patients drastically. If the correct pathogen is not detected on the first try using singleplex testing, then subsequent tests are just an added cost which also takes patients time till the final diagnosis. Higher treatment costs due to later diagnosis and, thus, more aggressive treatment measures are big issues that can be addressed with the use of syndromic panels and decrease the personal and economic burden on the individual and their family/friends.

Market Challenges:

The Need for Better Reimbursement of Syndromic Tests: Syndromic panels have faster turnaround time and can save patients money in the long run. However, there is still a gap in the reimbursement of these panels. This is because not all syndromic panels are FDA-approved and thus are not reimbursed. Additionally, all home-use panels, including the ones approved by the FDA, are not reimbursed. This slows down the adoption of these syndromic panels, which can only increase to all income classes if either these panels are constantly reimbursed, or the cost of syndromic panels drastically decreases.

Lack of High-Complexity Testing Center: With the ongoing rapid advancements, new genomic platforms require significant capital investment and high-test volume to enable operation at scale and achieve competitive price points. Additionally, there is also difficulty in establishing and maintaining different technology platforms.

Market Opportunities:

Quick Access to Treatment and Reduced Use of Antibiotics: When diagnosed with an infectious disease, the most efficient cure for late-stage infections is antibiotics. This can be combated with the use of syndromic testing, as it can help to detect pathogens at the earliest stages. According to a report by Zhu et al. published in 2019, stated that antibiotic prescriptions could be reduced by 30% with the use of syndromic testing.

High Number of Synergic Activities and Mergers and Acquisitions: The acute care syndromic testing market has witnessed many synergistic activities and mergers and acquisitions since January 2020. This is leading to the consolidation of the market. In June 2022, R-Biopharm acquired AusDiagnostics and with it their wide range of syndromic diseases testing product range.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global acute care syndromic testing market has been extensively segmented on the basis of various categories, such as disease type, target, sample type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments, i.e., nearly 91% of the total developments in the global acute care syndromic testing market were between January 2021 to June 2023.

Competitive Strategy: The global acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the global acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top disease-type segment players who are leading capture around 56.30% of the presence in the market. Players in other industries, such as gastrointestinal, genitourinary, and tropical disease, among others, account for approximately 43.70% of the presence in the market.

Key Companies Profiled:

• Abbott Laboratories
• Becton, Dickinson and Company
• Biocartis NV
• bioMérieux SA (BioFire Diagnostics)
• Danaher Corporation (Cepheid, Inc.)
• DiaSorin S.p.A (Luminex Corporation)
• Eurofins Scientific (Eurofins Viracor)
• Karius
• Laboratory Corporation of America Holdings.
• QIAGEN N.V.
• QuantuMDx Group Ltd.
• Seegene Inc.
• Siemens Healthineers AG
• SpeeDx
• Thermo Fisher Scientific Inc.

ページTOPに戻る

Table of Contents

1 Markets
1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.3 Market Scope
1.3.1 Scope of the Study
1.3.2 Key Questions Answered in the Report
1.4 Research Methodology
1.4.1 Global Acute Care Syndromic Testing Market: Research Methodology
1.4.2 Data Sources
1.4.2.1 Primary Data Sources
1.4.2.2 Secondary Data Sources
1.4.3 Market Estimation Model
1.4.4 Criteria for Company Profiling
2 Market Overview
2.1 Overview
2.2 Acute Care Syndromic Testing Workflow Analysis
2.3 Market Footprint and Growth Potential
2.4 Future Potential
3 Industry Insight
3.1 Stakeholder’s Perspective (N=20)
3.1.1 Physician’s Perception
3.1.2 Payor’s Perception
3.1.3 Investor’s Perception
3.2 Legal and Regulatory Framework of the Global Acute Care Syndromic Testing Market
3.2.1 Regulatory Framework in North America
3.2.1.1 The U.S.
3.2.1.2 Canada
3.2.2 Regulatory Framework in Europe
3.2.3 Regulatory Framework in Asia-Pacific
3.2.3.1 Japan
3.2.3.2 China
3.2.3.3 India
3.2.3.4 South Korea
3.2.3.5 Australia
3.2.4 Regulatory Framework in Latin America
3.2.4.1 Brazil
3.2.4.2 Mexico
3.2.5 Regulatory Framework in Rest-of-the-World
3.2.5.1 U.A.E.
3.2.5.2 K.S.A.
3.3 Product Benchmarking
4 Market Dynamics
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Faster Results Acquired with Syndromic Tests
4.3.2 Increasing Incidence of Infectious Diseases
4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
4.3.4 Reduced Severe Adverse Effects from Pathogens
4.4 Market Challenges
4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
4.4.2 Lack of High-Complexity Testing Centres
4.5 Market Opportunities
4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years
5 Competitive Insight
5.1 Overview
5.2 Key Strategies and Developments
5.2.1 Synergistic Activities
5.2.2 Product Launches and Product Approvals
5.2.3 Funding and Expansion
5.2.4 Mergers and Acquisitions
5.3 Market Share Analysis (2022)
5.4 Growth-Share Analysis (2022)
5.4.1 Growth-Share Analysis (by Disease Type)
5.4.2 Growth-Share Analysis (by Target)
6 Global Acute Care Syndromic Testing Market (By Disease Type), 2022-2033
6.1 Overview
6.2 Competitive Analysis
6.3 Respiratory Diseases
6.3.1 Upper Respiratory Tract Infections
6.3.2 Lower Respiratory Tract Infections
6.4 Gastrointestinal Diseases
6.5 Genitourinary Diseases
6.5.1 Urinary Tract Infections
6.5.2 Sexually Transmitted Diseases
6.6 Tropical Diseases
6.7 Others
7 Global Acute Care Syndromic Testing Market (By Target), 2022-2033
7.1 Overview
7.2 Bacteria
7.2.1 Gram-Positive Bacteria
7.2.2 Gram-Negative Bacteria
7.3 Viruses
7.4 Fungi
7.5 Parasites
8 Global Acute Care Syndromic Testing Market (By Sample Type), 2022-2033
8.1 Overview
8.2 Blood
8.3 Urine
8.4 Biofluids
8.4.1 Saliva
8.4.2 Sputum
8.5 Stool
8.6 Swabs
8.6.1 Genital Swabs
8.6.2 Nasopharyngeal Swabs
8.7 Other Sample Types
9 Global Acute Care Syndromic Testing Market (By End User), 2022-2033
9.1 Overview
9.2 Hospitals
9.3 Clinical and Diagnostic Laboratories
9.4 Research and Academic Institutions
9.5 Other End Users
10 Global Acute Care Syndromic Testing Market (By Region), 2022-2033
10.1 Overview
10.2 North America
10.2.1 North America Acute Care Syndromic Testing Market, By End User
10.2.2 North America Acute Care Syndromic Testing Market, By Country
10.2.2.1 U.S.
10.2.2.2 Canada
10.3 Asia-Pacific
10.3.1 Asia-Pacific Acute Care Syndromic Testing Market, By End User
10.3.2 Asia-Pacific Acute Care Syndromic Testing Market, By Country
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 India
10.3.2.4 Australia
10.3.2.5 South Korea
10.3.2.6 Rest-of-Asia-Pacific
10.4 Europe
10.4.1 Europe Acute Care Syndromic Testing Market, By End User
10.4.2 Europe Acute Care Syndromic Testing Market, By Country
10.4.2.1 Germany
10.4.2.2 France
10.4.2.3 U.K.
10.4.2.4 Italy
10.4.2.5 Spain
10.4.2.6 Rest-of-Europe
10.5 Latin America
10.5.1 Latin America Acute Care Syndromic Testing Market, By End User
10.5.2 Latin America Acute Care Syndromic Testing Market, By Country
10.5.2.1 Brazil
10.5.2.2 Mexico
10.5.2.3 Rest-of-Latin America
10.6 Rest-of-the-World
10.6.1 Rest-of-the-World Acute Care Syndromic Testing Market, By End User
11 Company Profiles
11.1 Overview
11.2 Acute Care Syndromic Testing Ecosystem Active Players
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Role of Abbott Laboratories in the Global Acute Care Syndromic Testing Market
11.3.3 Financials
11.3.4 Recent Developments
11.3.4.1 Corporate Strategies
11.3.4.2 Business Strategies
11.3.5 Analyst Perspective
11.4 Becton, Dickinson and Company
11.4.1 Company Overview
11.4.2 Role of Becton, Dickinson and Company in the Global Acute Care Syndromic Testing Market
11.4.3 Financials
11.4.4 Recent Developments
11.4.4.1 Corporate Strategies
11.4.4.2 Business Strategies
11.4.5 Analyst Perspective
11.5 Biocartis NV
11.5.1 Company Overview
11.5.2 Role of Biocartis NV in the Global Acute Care Syndromic Testing Market
11.5.3 Financials
11.5.4 Recent Developments
11.5.4.1 Business Strategies
11.5.5 Analyst Perspective
11.6 bioMérieux SA (BioFire Diagnostics)
11.6.1 Company Overview
11.6.2 Role of bioMérieux SA (BioFire Diagnostics) in the Global Acute Care Syndromic Testing Market
11.6.3 Financials
11.6.4 Recent Developments
11.6.4.1 Business Strategies
11.6.5 Analyst Perspective
11.7 Danaher Corporation (Cepheid, Inc.)
11.7.1 Company Overview
11.7.2 Role of Danaher Corporation (Cepheid, Inc.) in the Global Acute Care Syndromic Testing Market
11.7.3 Financials
11.7.4 Recent Developments
11.7.4.1 Corporate Strategies
11.7.4.2 Business Strategies
11.7.5 Analyst Perspective
11.8 DiaSorin S.p.A (Luminex Corporation)
11.8.1 Company Overview
11.8.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Global Acute Care Syndromic Testing Market
11.8.3 Financials
11.8.4 Recent Developments
11.8.4.1 Corporate Strategies
11.8.4.2 Business Strategies
11.8.5 Analyst Perspective
11.9 Eurofins Scientific (Eurofins Viracor)
11.9.1 Company Overview
11.9.2 Role of Eurofins Scientific (Eurofins Viracor) in the Global Acute Care Syndromic Testing Market
11.9.3 Financials
11.9.4 Recent Developments
11.9.4.1 Business Strategies
11.9.5 Analyst Perspective
11.1 Karius
11.10.1 Company Overview
11.10.2 Role of Karius in the Global Acute Care Syndromic Testing Market
11.10.3 Recent Developments
11.10.3.1 Business Strategies
11.10.4 Analyst Perspective
11.11 Laboratory Corporation of America Holdings.
11.11.1 Company Overview
11.11.2 Role of Laboratory Corporation of America Holdings. in the Global Acute Care Syndromic Testing Market
11.11.3 Financials
11.11.4 Analyst Perspective
11.12 QIAGEN N.V.
11.12.1 Company Overview
11.12.2 Role of QIAGEN N.V. in the Global Acute Care Syndromic Testing Market
11.12.3 Financials
11.12.4 Recent Developments
11.12.4.1 Business Strategies
11.12.5 Analyst Perspective
11.13 QuantuMDx Group Ltd.
11.13.1 Company Overview
11.13.2 Role of QuantuMDx Group Ltd. in the Global Acute Care Syndromic Testing Market
11.13.3 Recent Developments
11.13.3.1 Corporate Strategies
11.13.3.2 Business Strategies
11.13.4 Analyst Perspective
11.14 Seegene Inc.
11.14.1 Company Overview
11.14.2 Role of Seegene, Inc. in the Global Acute Care Syndromic Testing Market
11.14.3 Financials
11.14.4 Recent Developments
11.14.4.1 Corporate Strategies
11.14.4.2 Business Strategies
11.14.5 Analyst Perspective
11.15 Siemens Healthineers AG
11.15.1 Company Overview
11.15.2 Role of Siemens Healthineers AG in the Global Acute Care Syndromic Testing Market
11.15.3 Financials
11.15.4 Analyst Perspective
11.16 SpeeDx
11.16.1 Company Overview
11.16.2 Role of SpeeDX in the Global Acute Care Syndromic Testing Market
11.16.3 Analyst Perspective
11.17 Thermo Fisher Scientific Inc.
11.17.1 Company Overview
11.17.2 Role of Thermo Fisher Scientific Inc. in the Global Acute Care Syndromic Testing Market
11.17.3 Financials
11.17.4 Recent Developments
11.17.4.1 Business Strategies
11.17.5 Analyst Perspective
List of Figures
Figure 1: Global Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
Figure 2: History of Known Pandemics
Figure 3: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 4: Global Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
Figure 5: Global Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
Figure 6: Share of Global Acute Care Syndromic Testing Market (by Region), 2022
Figure 7: Share of Key Developments and Strategies, January 2020-June 2023
Figure 8: Global Acute Care Syndromic Testing Market (by Company), Share (%), 2022
Figure 9: Global Acute Care Syndromic Testing Market Segmentation
Figure 10: Global Acute Care Syndromic Testing Market: Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Acute Care Syndromic Testing Workflow
Figure 15: Global Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 16: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
Figure 17: Global Acute Care Syndromic Testing Market Dynamics
Figure 18: Traditional Testing vs. Syndromic Testing
Figure 19: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 20: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
Figure 21: Incidence of Common Infectious Diseases in China, 2020
Figure 22: History of Known Pandemics
Figure 23: Examples of Cost Reductions
Figure 24: Time of Diagnosis vs. Disease Effect
Figure 25: Syndromic Panels Reimbursement Scenario in the U.S.
Figure 26: Syndromic Panels Reimbursement Scenario in Mexico
Figure 27: Reduction in Antibiotics Use with Syndromic Testing
Figure 28: Increasing Synergistic Activities of the Global Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
Figure 29: Key Mergers and Acquisitions in the Global Acute Care Syndromic Testing Market
Figure 30: Share of Key Developments and Strategies, January 2020-June 2023
Figure 31: Share of Synergistic Activities (by Company), January 2020-June 2023
Figure 32: Number of Product Launches and Product Approvals (by Company), January 2020-June 2023
Figure 33: Number of Mergers and Acquisitions (by Company), January 2020-June 2023
Figure 34: Global Acute Care Syndromic Testing Market (by Company), Share (%), 2022
Figure 35: Global Acute Care Syndromic Testing Market, Growth-Share Matrix (by Disease Type), 2023-2033
Figure 36: Global Acute Care Syndromic Testing Market, Growth-Share Matrix (by Target), 2023-2033
Figure 37: Global Acute Care Syndromic Testing Market (by Disease Type)
Figure 38: Global Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
Figure 39: Global Acute Care Syndromic Testing Market (Respiratory Diseases), $Billion, 2022-2033
Figure 40: Global Acute Care Syndromic Testing Market (Upper Respiratory Tract Infections), $Billion, 2022-2033
Figure 41: Global Acute Care Syndromic Testing Market (Lower Respiratory Tract Infections), $Billion, 2022-2033
Figure 42: Global Acute Care Syndromic Testing Market (Gastrointestinal Diseases), $Billion, 2022-2033
Figure 43: Global Acute Care Syndromic Testing Market (Genitourinary Diseases), $Billion, 2022-2033
Figure 44: Global Acute Care Syndromic Testing Market (Urinary Tract Infections), $Billion, 2022-2033
Figure 45: Global Acute Care Syndromic Testing Market (Sexually Transmitted Diseases), $Billion, 2022-2033
Figure 46: Global Acute Care Syndromic Testing Market (Tropical Diseases), $Billion, 2022-2033
Figure 47: Global Acute Care Syndromic Testing Market (Others), $Billion, 2022-2033
Figure 48: Global Acute Care Syndromic Testing Market (by Target)
Figure 49: Global Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
Figure 50: Global Acute Care Syndromic Testing Market (Bacteria), $Billion, 2022-2033
Figure 51: Global Acute Care Syndromic Testing Market (Gram-Positive Bacteria), $Billion, 2022-2033
Figure 52: Global Acute Care Syndromic Testing Market (Gram-Negative Bacteria), $Billion, 2022-2033
Figure 53: Global Acute Care Syndromic Testing Market (Viruses), $Billion, 2022-2033
Figure 54: Global Acute Care Syndromic Testing Market (Fungi), $Billion, 2022-2033
Figure 55: Global Acute Care Syndromic Testing Market (Parasites), $Billion, 2022-2033
Figure 56: Global Acute Care Syndromic Testing Market (by Sample Type)
Figure 57: Global Acute Care Syndromic Testing Market (by Sample Type), Share (%), 2022 and 2033
Figure 58: Global Acute Care Syndromic Testing Market (Blood), $Billion, 2022-2033
Figure 59: Global Acute Care Syndromic Testing Market (Urine), $Billion, 2022-2033
Figure 60: Global Acute Care Syndromic Testing Market (Biofluids), $Billion, 2022-2033
Figure 61: Global Acute Care Syndromic Testing Market (Saliva), $Billion, 2022-2033
Figure 62: Global Acute Care Syndromic Testing Market (Sputum), $Billion, 2022-2033
Figure 63: Global Acute Care Syndromic Testing Market (Stool), $Billion, 2022-2033
Figure 64: Global Acute Care Syndromic Testing Market (Swabs), $Billion, 2022-2033
Figure 65: Global Acute Care Syndromic Testing Market (Genital Swab), $Billion, 2022-2033
Figure 66: Global Acute Care Syndromic Testing Market (Nasopharyngeal Swabs), $Billion, 2022-2033
Figure 67: Global Acute Care Syndromic Testing Market (Other Sample Types), $Billion, 2022-2033
Figure 68: Global Acute Care Syndromic Testing Market (by End User)
Figure 69: Global Acute Care Syndromic Testing Market (by End User), Share (%), 2022 and 2033
Figure 70: Global Acute Care Syndromic Testing Market (Hospitals), $Billion, 2022-2033
Figure 71: Global Acute Care Syndromic Testing Market (Clinical and Diagnostic Laboratories), $Billion, 2022-2033
Figure 72: Global Acute Care Syndromic Testing Market (Research and Academic Institutions), $Billion, 2022-2033
Figure 73: Global Acute Care Syndromic Testing Market (Other End Users), $Billion, 2022-2033
Figure 74: Global Acute Care Syndromic Testing Market Snapshot (by Region)
Figure 75: Global Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
Figure 76: North America Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 77: North America Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
Figure 78: North America Acute Care Syndromic Testing Market (by Country), $Billion, 2022-2033
Figure 79: Top Five Infectious Diseases in the U.S., 2019
Figure 80: U.S. Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 81: Canada Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 82: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 83: Asia-Pacific Acute Care Syndromic Testing Market (by End User), $Billion, 2022-2033
Figure 84: Asia-Pacific Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 85: Reported Cases of Top 5 Infectious Diseases, China, 2020
Figure 86: China Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 87: Japan Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 88: India Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 89: Incidence of the Most Common Infectious Diseases in Australia, 2021
Figure 90: Australia Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 91: South Korea Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 92: Rest-of-Asia-Pacific Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 93: Europe Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 94: Europe Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
Figure 95: Europe Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 96: Top 5 Most Common Infectious Diseases in Germany, 2020
Figure 97: Germany Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 98: France Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 99: U.K. Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 100: Italy Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 101: Spain Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 102: Rest-of-Europe Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 103: Latin America Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 104: Latin America Acute Care Syndromic Testing Market (by End User), $Million, 2022-2033
Figure 105: Latin America Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 106: Brazil Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 107: Mexico Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 108: Rest-of-Latin America Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 109: Rest-of-the-World Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 110: Rest-of-the-World Acute Care Syndromic Testing Market (by End User), $Million, 2023-2033
Figure 111: Global Acute Care Syndromic Testing Market, Total Number of Companies Profiled
Figure 112: Abbott Laboratories: Product Portfolio
Figure 113: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 114: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
Figure 115: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
Figure 116: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 117: Becton, Dickinson and Company: Product Portfolio
Figure 118: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
Figure 119: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
Figure 120: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
Figure 121: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
Figure 122: Biocartis NV: Product Portfolio
Figure 123: Biocartis NV: Overall Financials, $Million, 2020-2022
Figure 124: Biocartis NV: R&D Expenditure, $Million, 2020-2022
Figure 125: bioMérieux SA (BioFire Diagnostics): Product Portfolio
Figure 126: bioMérieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
Figure 127: bioMérieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
Figure 128: bioMérieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
Figure 129: bioMérieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
Figure 130: Danaher Corporation (Cepheid, Inc.): Product Portfolio
Figure 131: Danaher Corporation (Cepheid, Inc.): Overall Financials, $Million, 2020-2022
Figure 132: Danaher Corporation (Cepheid, Inc.): Revenue (by Segment), $Million, 2020-2022
Figure 133: Danaher Corporation (Cepheid, Inc.): Revenue (by Region), $Million, 2020-2022
Figure 134: Danaher Corporation (Cepheid, Inc.): R&D Expenditure, $Million, 2020-2022
Figure 135: DiaSorin S.p.A (Luminex Corporation): Product Portfolio
Figure 136: DiaSorin S.p.A (Luminex Corporation): Overall Financials, $Million, 2021 and 2022
Figure 137: DiaSorin S.p.A (Luminex Corporation): Revenue (by Region), $Million, 2021 and 2022
Figure 138: DiaSorin S.p.A (Luminex Corporation): R&D Expenditure, $Million, 2021 and 2022
Figure 139: Eurofins Scientific (Eurofins Viracor): Product Portfolio
Figure 140: Eurofins Scientific (Eurofins Viracor): Overall Financials, $Million, 2020-2022
Figure 141: Eurofins Scientific (Eurofins Viracor): Revenue (by Segment), $Million, 2020-2022
Figure 142: Eurofins Scientific (Eurofins Viracor): Revenue (by Region), $Million, 2020-2022
Figure 143: Karius: Product Portfolio
Figure 144: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 145: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 146: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 147: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 148: QIAGEN N.V.: Product Portfolio
Figure 149: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 150: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 151: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 152: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 153: QuantuMDx Group Ltd.: Product Portfolio
Figure 154: Seegene, Inc.: Product Portfolio
Figure 155: Seegene, Inc.: Overall Financials, $Million, 2020-2022
Figure 156: Seegene, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 157: Seegene, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 158: Seegene, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 159: Siemens Healthineers AG: Product Portfolio
Figure 160: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 161: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 162: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 163: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 164: SpeeDX: Product Portfolio
Figure 165: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 166: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 167: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 168: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 169: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
List of Tables
Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
Table 2: Global Acute Care Syndromic Testing Market: Impact Analysis
Table 3: Key Questions Answered in the Report
Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
Table 5: Likert Scale
Table 6: Impact Analysis of Market Drivers
Table 7: Impact Analysis of Market Challenges
Table 8: Popular Assays and Their Turnaround Times
Table 9: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
Table 10: List of FDA-Cleared Upper Respiratory Tract Syndromic Panels
Table 11: Common Upper Tract Respiratory Infections Panels and Key Pathogens being Tested
Table 12: List of FDA-Cleared Lower Respiratory Tract Syndromic Panels
Table 13: Common Gastrointestinal Diseases Panels and Key Pathogens being Tested
Table 14: Common Genitourinary Diseases Panels and Key Pathogens being Tested
Table 15: Common Other Diseases Panels and Key Pathogens being Tested
Table 16: Global Acute Care Syndromic Testing Ecosystem Active Players

Press Release